[1]刘伟,傅光涛,胡旭民,等.唑来膦酸治疗绝经后骨质疏松发生脆性骨折的临床研究[J].中华老年骨科与康复电子杂志,2017,(06):351-355.[doi:10.3877/cma.j.issn.2096-0263.2017.06.007]
　Liu Wei,Fu Guangtao,Hu Xumin,et al.Analysis in postmenopausal osteoporosis patients with fragility fracture during zoledronic acid treatment[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(06):351-355.[doi:10.3877/cma.j.issn.2096-0263.2017.06.007]
点击复制

唑来膦酸治疗绝经后骨质疏松发生脆性骨折的临床研究()
分享到：

中华老年骨科与康复电子杂志[ISSN:1674-3911/CN:11-9292/R]

卷:
期数:
2017年06期
页码:
351-355
栏目:
论著
出版日期:
2017-11-27

文章信息/Info

Title:
Analysis in postmenopausal osteoporosis patients with fragility fracture during zoledronic acid treatment
作者:
刘伟; 傅光涛 ; 胡旭民 ; 李长川; 李春海 ;  叶艳芳; 丁悦
510120 广州，中山大学孙逸仙纪念医院骨科 1，临床试验设计部 2
Author(s):
Liu Wei1;  Fu Guangtao1;  Hu Xumin1;  Li Changchuan1;  Li Chunhai1;  Ye Yanfang2;  Ding Yue1
1Department of Orthopaedics, 2Department of Clinical trial design, Sun Yat-Sen Memorial Hospital, Sun YatSen University, Guangzhou 510120, China
关键词:
骨质疏松症; 绝经后;  唑来膦酸;  脆性骨折
Keywords:
Osteoporosis;  postmenopausal;  Zoledronic acid;  Fragility fracture
DOI:
10.3877/cma.j.issn.2096-0263.2017.06.007
文献标志码:
A
摘要:
目的 比较绝经后骨质疏松症患者在使用唑来膦酸治疗过程中是否发生脆性骨折的临床研究。方法 本研究回顾性分析 2010年 1月至 2017年 1月于中山大学孙逸仙纪念医院就诊的绝经后骨质疏松症且已行一次及以上唑来膦酸治疗的患者 270例。根据使用唑来磷酸治疗过程中是否出现脆性骨折分为脆性骨折组（n=10）及无脆性骨折组（n=260），比较两组既往脆性骨折史、年龄、基线 BMI、基线骨密度、ALP、25（OH）2VitD。结果 270例患者获得满意随访，随访率100%，平均治疗时间（2.4±0.5）年。与无脆性骨折组相比，脆性骨折组合并既往骨折史的比例更高（c2=79.286，P＜0.05），脆性骨折组患者基线腰椎、股骨颈区域骨密度、T 值更低（t=-2.736，t=-2.170，t=-3.030，t=-2.271，P＜0.05）。但组间基线 BMI、ALP、25(OH)2VitD水平无显著性差异。结论 绝经后骨质疏松患者在钙、维生素 D摄入充分，治疗依从性良好的情况下，使用唑来膦酸进行治疗时，脆性骨折患者合并既往骨折史的比例更高、基线腰椎、股骨颈区域骨密度、T值更低。
Abstract:
Objective To analyze possible factors of fragility fracture during zoledronic acid (ZOL) treatment in postmenopausal osteoporosis patients (PMOP). Methods A retrospective study of 270 cases that received at least one ZOL treatment after confirmed PMOP from January 2010 to January 2017 in Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University were included. All patients were divided into two groups based on the presence of fragility fracture during ZOL treatment, fragility fracture group had 10 cases and the non-fragility fracture group had 260 cases. Previous fragility fracture history, age, BMI, bone mineral density (BMD), ALP, 25(OH)2VitD at baseline were compared between two groups. Results Fortyeight patients combined with previous fragility fracture history. Ten patients experienced fragility fracture during ZOL treatment. The proportion of the cases combined with previous fragility fracture history in fragility fracture group was significantly higher than that in the control group (c2=79.286, P<0.05). The baseline of BMD and T-score of the fragility fracture group was significantly lower than that of the control group (t=-2.736, t=-2.170, t=-3.030, t=-2.271, P<0.05). While there were no significant difference of age, BMI, ALP, 25-hydroxy vitamin D at the baseline between two groups. Conclusion Under the condition of adequate intake of calcium, vitamin D and good compliance, The proportion of the cases combined with previous fragility fracture history in the fragility fracture group was significantly higher than that of the control group. The baseline of BMD and T-score of the fragility fracture group was significantly lower than that of the control group.

参考文献/References:

1 Ellis AG, Reginster JY, Luo X, et al. Bazedoxifene versus oral bisphosphonates for the Prevention of Nonvertebral Fractures in postmenopausal women with Osteoporosis at higher risk of fracture: a network meta-analysis [J]. Value Health, 2014, 17(4): 424-432.
2 黎慧萍, 余寿益, 刘继洪. BMD、OSTA和 FRAX对绝经后骨质疏松症患者骨折的预测价值分析 [J]. 中国医学创新, 2016, 13(2): 48-49.
3 北京协和医院. 老年医学诊疗常规 [M] . 北京: 人民卫生出版社, 2012: 103-108.
4 《骨质疏松症中国蓝皮书》，中国老年学学会骨质疏松委员会， 2013.11.24 http://www.cqvip.com/QK/91449X/201319/47796102. html
5 Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT) [J]. J Bone Miner Res, 2015, 30(5): 934-944.
6 Prieto-Alhambra D, Pagès-Castellà A, Wallace G, et al. Predictors of fracture while on treatment with oral bisphosphonates: a populationbased cohort study [J]. J Bone Miner Res, 2014, 29(1): 268-274.
7 Díez- Pérez A, Olmos JM, Nogués X, et al. Risk factors for prediction of inadequate response to antiresorptives [J]. J Bone Miner Res, 27(4): 817-824
8 J. Compston, A. Cooper, C. Cooper, N，et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017; 12(1): 43.
9 中国成人超重和肥胖症预防与控制指南, 中华人民共和国卫生部疾病控制司，《营养学报》2004年 第 1期 http://www.cqvip.com/QK/ 95640X/200401/9215804.html
10 Cairoli E, Eller- Vainicher C, Ulivieri FM, et al. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis [J]. Osteoporos Int, 2014, 25(4): 1401- 1410.
11 Ferrari S, Reginster JY, Brandi ML, et al. Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture [J]. Arch Osteoporos, 2016, 11(1): 37.
12 Curtis EM, Harvey NC. S D’angelo,CS cooper,KA ward,P taylor,G pearson,C cooper,bone mineral content and areal density,but not bone area,predict incident fracture risk:a comparative study in a UK prospective cohort [J]. Arch Osteoporos, 2016, 11(1): 39.
13 Vestergaard P. Bone diseases. Incident fractures during treatment for osteoporosis [J]. Nat Rev Rheumatol, 2013, 9(9): 508-510.

相似文献/References:

[1]马晓龙,刘强,吴斗,等.骨质疏松显微骨折早期发生发展过程的实验研究[J].中华老年骨科与康复电子杂志,2016,(03):129.[doi:10.3877/cma.j.issn.2096-0263.2016.03.001]
　Ma Xiaolong,Liu Qiang,Wu Dou,et al.Experimental study of osteoporotic microsurgery fractures in the early development process[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(06):129.[doi:10.3877/cma.j.issn.2096-0263.2016.03.001]
[2]崔红旺,蒋电明.骨细胞程序性死亡在骨质疏松中作用的研究进展[J].中华老年骨科与康复电子杂志,2016,(03):181.[doi:10.3877/cma.j.issn.2096-0263.2016.03.011]
　Cui Hongwang,Jiang Dianming.Effect of the programmed cell death of osteocyte on osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(06):181.[doi:10.3877/cma.j.issn.2096-0263.2016.03.011]
[3]李子怡,李玉坤.OPG/RANK/RANKL信号通路在骨质疏松症中的研究进展和应用[J].中华老年骨科与康复电子杂志,2017,(02):124.[doi:10.3877/cma.j.issn.2096-0263.2017.02.012]
　Li Ziyi,Li Yukun.Researching progress and application of OPG-RANK-RANKL signaling pathway in osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(06):124.[doi:10.3877/cma.j.issn.2096-0263.2017.02.012]
[4]雷涛,申勇.老年骨质疏松性椎体骨折若干问题的探讨[J].中华老年骨科与康复电子杂志,2017,(04):248.[doi:10.3877/cma.j.issn.2096-0263.2017.04.010]
　Lei Tao,Shen Yong..A brief discussion of osteoporotic vertebral fractures in elderly patients[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(06):248.[doi:10.3877/cma.j.issn.2096-0263.2017.04.010]
[5]马树伟.球囊扩张椎体成形术治疗急性与亚急性期骨质疏松椎体压缩骨折的疗效对比[J].中华老年骨科与康复电子杂志,2017,(06):341.[doi:10.3877/cma.j.issn.2096-0263.2017.06.005]
　Ma Shuwei.Clinical efficacy of percutaneous kyphoplasty in the treatment of acute and subacute phase of osteoporotic vertebral compression fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(06):341.[doi:10.3877/cma.j.issn.2096-0263.2017.06.005]
[6]邢浩,刘强,吴斗,等.双膦酸盐治疗股骨非典型性骨折的研究进展[J].中华老年骨科与康复电子杂志,2018,(02):118.[doi:10.3877/cma.j.issn.2096-0263.2018.02.010]
　Bisphosphonates and atypical femur fractures femur[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(06):118.[doi:10.3877/cma.j.issn.2096-0263.2018.02.010]
[7]梁伟,吴斗,赵恩哲,等.皮质厚度在骨质疏松性髋部骨折中的应用研究[J].中华老年骨科与康复电子杂志,2018,(03):184.[doi:10.3877/cma.j.issn.2096-0263.2018.03.012]
　Liang Wei,Wu Dou,Zhao Enzhe,et al.Application research of Cortical thickness in osteoporotic hip fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(06):184.[doi:10.3877/cma.j.issn.2096-0263.2018.03.012]
[8]谢亚明,谢国盛,林蒙,等.网袋成形术与椎体后凸成形术治疗骨质疏松性椎体压缩骨折的早期疗效比较[J].中华老年骨科与康复电子杂志,2018,(04):202.[doi:10.3877/cma.j.issn.2096-0263.2018.04.003]
　Xie Yaming,Xie Guosheng,Lin Meng,et al.Early clinical outcome of vesselplasty and kyphoplasty in treatment of osteoporotic vertebral compression fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(06):202.[doi:10.3877/cma.j.issn.2096-0263.2018.04.003]
[9]吴石磊 刘勇 邵增务 田青. 骨组织细胞外泌体对骨代谢作用的研究现状[J].中华老年骨科与康复电子杂志,2018,(05):308.
　Wu Shilei,Liu Yong,Shao Zengwu,et al. Research status of bone tissue-derived exosomes on bone metabolism[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(06):308.
[10]郜振武 吴斗 高敏 朱剑 陈晨 孙吉平 刘强. 骨质疏松性骨折的药物治疗策略与选择[J].中华老年骨科与康复电子杂志,2018,(05):317.
　Gao Zhenwu,Wu Dou,Gao Min,et al. The drug treatment for strategy and selection of osteoporotic fracture[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(06):317.

备注/Memo

备注/Memo:
基金项目：广东省公益研究及能力建设重大专项（2014B020212004）；中山大学孙逸仙纪念医院逸仙临床研究培育项目（2014年）
更新日期/Last Update: 2017-11-28